27.55
price down icon2.27%   -0.64
 
loading

Alkermes Plc Aktie (ALKS) Neueste Nachrichten

pulisher
Nov 16, 2024

Brokerages Set Alkermes plc (NASDAQ:ALKS) PT at $35.42 - MarketBeat

Nov 16, 2024
pulisher
Nov 13, 2024

Alkermes (NASDAQ:ALKS) Price Target Raised to $40.00 at Mizuho - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Alkermes plc (NASDAQ:ALKS) Shares Sold by Principal Financial Group Inc. - MarketBeat

Nov 13, 2024
pulisher
Nov 11, 2024

Alkermes to Participate in Two Upcoming Investor Conferences - Lelezard

Nov 11, 2024
pulisher
Nov 11, 2024

Alkermes (ALKS) to Present at Major Healthcare Conferences: Stifel and Jefferies London | ALKS Stock News - StockTitan

Nov 11, 2024
pulisher
Nov 10, 2024

Trend Tracker for (ALKS) - Stock Traders Daily

Nov 10, 2024
pulisher
Nov 10, 2024

Alkermes plc (NASDAQ:ALKS) Shares Purchased by Robeco Institutional Asset Management B.V. - MarketBeat

Nov 10, 2024
pulisher
Nov 10, 2024

Van ECK Associates Corp Purchases 29,998 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat

Nov 10, 2024
pulisher
Nov 08, 2024

Wellington Management Group LLP Adjusts Stake in Alkermes PLC - GuruFocus.com

Nov 08, 2024
pulisher
Nov 07, 2024

Narcolepsy Insights from Alkermes Presented at Psych Congress and NEI Congress - Sleep Review

Nov 07, 2024
pulisher
Nov 07, 2024

Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences - PR Newswire

Nov 07, 2024
pulisher
Nov 07, 2024

Alkermes EVP Craig Hopkinson sells $309,168 in stock - Investing.com

Nov 07, 2024
pulisher
Nov 07, 2024

Alkermes EVP Craig Hopkinson sells $309,168 in stock By Investing.com - Investing.com Australia

Nov 07, 2024
pulisher
Nov 06, 2024

Insider Sale at Alkermes PLC: EVP R&D, Chief Medical Officer Cra - GuruFocus.com

Nov 06, 2024
pulisher
Nov 06, 2024

Alkermes raised to buy by Stifel on increased confidence for ALKS2680 - MSN

Nov 06, 2024
pulisher
Nov 05, 2024

Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - GuruFocus.com

Nov 05, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Recent Transaction in Alkermes PLC Shares - GuruFocus.com

Nov 05, 2024
pulisher
Nov 05, 2024

Alkermes (NASDAQ:ALKS) Shares Gap UpHere's What Happened - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Alkermes raised to buy by Stifel on increased confidence for ALKS2680 (NASDAQ:ALKS) - Seeking Alpha

Nov 05, 2024
pulisher
Nov 05, 2024

Alkermes PLC (ALKS) Shares Up 5.57% on Nov 5 - GuruFocus.com

Nov 05, 2024
pulisher
Nov 05, 2024

Alkermes (NASDAQ:ALKS) Upgraded to Buy at Stifel Nicolaus - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

A Glimpse Into The Expert Outlook On Alkermes Through 9 Analysts - Benzinga

Nov 05, 2024
pulisher
Nov 05, 2024

Stifel raises Alkermes target to $36, upgrades to buy By Investing.com - Investing.com Australia

Nov 05, 2024
pulisher
Nov 04, 2024

Stifel raises Alkermes target to $36, upgrades to buy - Investing.com India

Nov 04, 2024
pulisher
Nov 04, 2024

Alkermes plc (NASDAQ:ALKS) Holdings Decreased by DekaBank Deutsche Girozentrale - MarketBeat

Nov 04, 2024
pulisher
Oct 30, 2024

(ALKS) Proactive Strategies - Stock Traders Daily

Oct 30, 2024
pulisher
Oct 30, 2024

Short Interest in Alkermes plc (NASDAQ:ALKS) Drops By 7.9% - MarketBeat

Oct 30, 2024
pulisher
Oct 29, 2024

Alkermes plc (NASDAQ:ALKS) Shares Sold by Allspring Global Investments Holdings LLC - MarketBeat

Oct 29, 2024
pulisher
Oct 29, 2024

Alkermes holds steady stock target with neutral rating amid royalty segment dip - Investing.com

Oct 29, 2024
pulisher
Oct 28, 2024

Alkermes holds steady stock target with neutral rating amid royalty segment dip By Investing.com - Investing.com South Africa

Oct 28, 2024
pulisher
Oct 28, 2024

Alkermes's SWOT analysis: innovative pipeline drives CNS stock's future - Investing.com

Oct 28, 2024
pulisher
Oct 28, 2024

Alkermes Eyes Completion of Phase 2 Narcolepsy Studies in 2025 - Sleep Review

Oct 28, 2024
pulisher
Oct 26, 2024

Goldman Sachs keeps Alkermes stock buy-rated ahead of milestone readouts, trims PT - Investing.com Canada

Oct 26, 2024
pulisher
Oct 25, 2024

Piper Sandler cuts Alkermes stock target, keeps Overweight rating By Investing.com - Investing.com Australia

Oct 25, 2024
pulisher
Oct 25, 2024

Leerink maintains Alkermes stock rating with $28 target amid financial projections - Investing.com Australia

Oct 25, 2024
pulisher
Oct 25, 2024

Leerink maintains Alkermes stock rating with $28 target amid financial projections By Investing.com - Investing.com South Africa

Oct 25, 2024
pulisher
Oct 25, 2024

Alkermes (NASDAQ:ALKS) PT Lowered to $30.00 - MarketBeat

Oct 25, 2024
pulisher
Oct 25, 2024

Piper Sandler cuts Alkermes stock target, keeps Overweight rating - Investing.com

Oct 25, 2024
pulisher
Oct 25, 2024

Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down - MSN

Oct 25, 2024
pulisher
Oct 25, 2024

Alkermes' Q3 Earnings & Revenues Fall Shy Of Estimates, Stock Down - Barchart

Oct 25, 2024
pulisher
Oct 25, 2024

Alkermes' (ALKS) Overweight Rating Reiterated at Piper Sandler - MarketBeat

Oct 25, 2024
pulisher
Oct 25, 2024

Alkermes plc (NASDAQ:ALKS) Q3 2024 Earnings Call Transcript - Insider Monkey

Oct 25, 2024
pulisher
Oct 25, 2024

Earnings call: Alkermes Plc reports solid Q3 growth, eyes future expansion - Investing.com

Oct 25, 2024
pulisher
Oct 25, 2024

Alkermes Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance

Oct 25, 2024
pulisher
Oct 25, 2024

Alkermes PLC (ALKS) Q3 2024 Earnings Call Highlights: Strong Pro - GuruFocus.com

Oct 25, 2024
pulisher
Oct 25, 2024

Substance Abuse Treatment Market to Witness Massive Growth (2024-2031)| Allergan PLC, Alkermes, Noramco. - openPR

Oct 25, 2024
pulisher
Oct 25, 2024

Alkermes PLC (ALKS) Q3 2024 Earnings Call Highlights: Strong Proprietary Product Growth and ... - Yahoo Finance

Oct 25, 2024
pulisher
Oct 24, 2024

Alkermes: Q3 Earnings Snapshot - mySA

Oct 24, 2024
pulisher
Oct 24, 2024

Alkermes' Q3 Proprietary Sales Soar 18% - The Motley Fool

Oct 24, 2024
$76.22
price down icon 0.79%
$13.45
price down icon 3.79%
$82.47
price down icon 1.14%
$58.78
price down icon 0.54%
$117.62
price up icon 0.15%
$13.00
price up icon 1.33%
Kapitalisierung:     |  Volumen (24h):